MAB Discovery GmbH
MAB Discovery GmbH signs Multi-Target Antibody Deal
MAB Discovery GmbH / Key word(s): Agreement MAB Discovery GmbH signs Multi-Target Antibody Deal Neuried, Germany; March 27, 2014: MAB Discovery GmbH, a privately held biotechnology company focused on applying its innovative drug discovery capabilities to the generation of novel antibody therapeutics, today announced it has entered into a collaboration with Genmab A/S (OMX: GEN) and its affiliate Genmab BV. Under the terms of the agreement, MAB Discovery will generate antibodies for multiple Genmab targets in support of their development of therapeutic antibody products. MAB Discovery will employ its in vivo antibody discovery technology platform, which relies on the natural immune response of rabbits followed by state of the art B-cell cloning techniques. Using a novel high-throughput screening route, MAB Discovery focuses on identifying highly active antibodies with unprecedented epitope coverage, potency and species-cross-reactivity which has been successful for intractable targets. This technology eliminates affinity maturation and surrogate development which is very time consuming. “We are excited to provide our rabbit-based in vivo platform to such a high quality biotech company” said Dr. Stephan Fischer, CEO of MAB Discovery, “Genmab’s antibody format technologies the DuoBody and HexaBody platforms, combined with our antibody discovery platform, could lead to the discovery of best in class therapeutic antibodies.” The deal terms are not disclosed. MAB Discovery was founded in Munich, Germany in October 2010. The team represents a group of scientists out of Roche Biologicals R&D with extensive experience in developing biologically based therapeutics. Funded by PPD Inc., MAB Discovery follows a collaboration-based business model as a basis for its partnerships. Because of their unique funding situation, MAB Discovery can employ flexible business models to meet the needs of their clients.
End of Corporate News 27.03.2014 Dissemination of a Corporate News, transmitted by DGAP – a company of EQS Group AG. The issuer is solely responsible for the content of this announcement. DGAP’s Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de |
259856 27.03.2014 |